Abivax Unveils Promising New Results from Obefazimod

Abivax has presented the latest data from its Phase 3 ABTECT study, in which Obefazimod demonstrated significant improvements in the management of moderately to severely active ulcerative colitis. In the trials, a daily dose of 50 mg demonstrated significant clinical improvement in patients with a prior inadequate response to advanced therapies, including after failure of JAK inhibitor treatments.

The study, which included 1,272 patients, revealed that obefazimod is well tolerated with a favorable safety profile. This announcement was made during UEG Week in Berlin, highlighting obefazimod's potential as a future standard-of-care treatment for this disease. Abivax management hosted a conference call to discuss these results and answer questions from investors.